Blood Safety Authority Shift To CDRH Opposed By Blood Centers
This article was originally published in The Gray Sheet
Executive Summary
Legislation shifting responsibility for the regulation of blood safety screening tests from FDA's Center for Biologics Evaluation and Research to the device center puts an enormous burden on blood organizations, according to America's Blood Centers (ABC)
You may also be interested in...
FDA Biologics Center Seeking To Address Device Industry Concerns – Zoon
Responsibility for the regulation of products related to blood safety should remain with FDA's Center for Biologics Evaluation & Research, according to CBER Director Kathryn Zoon
FDA Biologics Center Seeking To Address Device Industry Concerns – Zoon
Responsibility for the regulation of products related to blood safety should remain with FDA's Center for Biologics Evaluation & Research, according to CBER Director Kathryn Zoon
White House regulatory reform agenda
Office of Management and Budget is taking nominations for regs and guidance documents that impose "especially large burdens on small businesses and other small entities without an adequate benefit justification" for review. Issued March 18, 1OMB's draft report to Congress on the costs and benefits of federal regulations carries a 60-day comment period. HHS Secretary Thompson recently established a department-wide advisory panel on regulatory reform, set to meet March 20-21 in Phoenix. That panel is independently seeking comments on burdensome regulations (2"The Gray Sheet" March 18, 2002, p. 14). OMB also states that a "scientific advisory panel" including health and medical science experts will meet twice a year to evaluate Office of Information and Regulatory Affairs activities...